Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma

This study is looking at whether a liver stiffness scan (FibroScan) can be used to predict how well patients with advanced liver cancer (hepatocellular carcinoma, or HCC) will respond to immunotherapy treatment. It's an observational study — no new treatment is being tested; instead, researchers are studying whether this scan result can serve as a useful marker. **You may be eligible if...** - You have been diagnosed with advanced liver cancer (HCC), confirmed by imaging or biopsy - Your liver is still functioning reasonably well (Child-Pugh A) - You are well enough to carry out some daily activities (performance status of 2 or better) - You do not have high-risk varices (enlarged veins in the esophagus) or a history of variceal bleeding - You are eligible to receive immunotherapy **You may NOT be eligible if...** - You have already had locoregional therapy (like ablation or embolization) or a liver transplant - Your liver disease is very advanced (Child-Pugh C) - You have uncontrolled vascular problems, severe high blood pressure, or at risk of variceal bleeding - You have a severe autoimmune disorder - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.